James Gordon CFA
Stock Analyst at Barclays
(3.42)
# 2,342
Out of 5,055 analysts
132
Total ratings
58.9%
Success rate
5.3%
Average return
Main Sectors:
Stocks Rated by James Gordon CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: GSK GSK plc | Reiterated: Sell | 1,800p | 1,746p | +3.12% | 33 | Oct 14, 2026 | |
| SWX: NOVN Novartis AG | Reiterated: Hold | CHF 130.00 | CHF 119.78 | +8.53% | 13 | Oct 13, 2026 | |
| LON: AZN AstraZeneca PLC | Reiterated: Buy | 16,000p | 11,858p | +34.93% | 19 | Oct 13, 2026 | |
| SWX: SDZ Sandoz Group AG | Reiterated: Buy | CHF 93.00 | CHF 71.70 | +29.71% | 11 | Oct 12, 2026 | |
| SWX: GALD Galderma Group AG | Reiterated: Buy | CHF 220.00 | CHF 167.00 | +31.74% | 25 | Sep 30, 2026 | |
| SWX: ROP Roche Holding AG | Reiterated: Buy | CHF 410.00 → CHF 430.00 | CHF 361.00 | +19.11% | 14 | Sep 8, 2026 | |
| EPA: SAN Sanofi | Reiterated: Hold | €85.00 → €83.00 | €70.54 | +17.66% | 7 | Sep 8, 2026 | |
| LON: HIK Hikma Pharmaceuticals PLC | Upgraded: Hold | 1,350p → 1,700p | 1,588p | +7.05% | 4 | Sep 8, 2026 | |
| AMS: LKFT Lakefront Biotherapeutics NV | Reiterated: Sell | €22.00 | €25.66 | -14.26% | 3 | Sep 8, 2026 | |
| GMAB Genmab | Reiterated: Buy | n/a | $36.57 | - | 1 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $950 | $802.64 | +18.36% | 1 | Jul 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | kr 530.00 | kr 426.80 | +24.18% | 1 | Jul 3, 2026 |
GSK plc
Oct 14, 2026
Reiterated: Sell
Price Target: 1,800p
Current: 1,746p
Upside: +3.12%
Novartis AG
Oct 13, 2026
Reiterated: Hold
Price Target: CHF 130.00
Current: CHF 119.78
Upside: +8.53%
AstraZeneca PLC
Oct 13, 2026
Reiterated: Buy
Price Target: 16,000p
Current: 11,858p
Upside: +34.93%
Sandoz Group AG
Oct 12, 2026
Reiterated: Buy
Price Target: CHF 93.00
Current: CHF 71.70
Upside: +29.71%
Galderma Group AG
Sep 30, 2026
Reiterated: Buy
Price Target: CHF 220.00
Current: CHF 167.00
Upside: +31.74%
Roche Holding AG
Sep 8, 2026
Reiterated: Buy
Price Target: CHF 410.00 → CHF 430.00
Current: CHF 361.00
Upside: +19.11%
Sanofi
Sep 8, 2026
Reiterated: Hold
Price Target: €85.00 → €83.00
Current: €70.54
Upside: +17.66%
Hikma Pharmaceuticals PLC
Sep 8, 2026
Upgraded: Hold
Price Target: 1,350p → 1,700p
Current: 1,588p
Upside: +7.05%
Lakefront Biotherapeutics NV
Sep 8, 2026
Reiterated: Sell
Price Target: €22.00
Current: €25.66
Upside: -14.26%
Genmab
Aug 7, 2026
Reiterated: Buy
Price Target: n/a
Current: $36.57
Upside: -
Jul 24, 2026
Reiterated: Buy
Price Target: $950
Current: $802.64
Upside: +18.36%
Jul 3, 2026
Reiterated: Buy
Price Target: kr 530.00
Current: kr 426.80
Upside: +24.18%